Infections in Surgery of Primary Tumors of the Sacrum
Chordoma
DOI:
10.1097/brs.0b013e3182213a44
Publication Date:
2012-02-25T17:16:09Z
AUTHORS (4)
ABSTRACT
In Brief Study Design. Retrospective case series. Objective. To evaluate the risk of infection, related treatment, and outcome after surgery 2 most common primary sacral tumors. Summary Background Data. Rarity tumors has limited number population-based studies. Treatment depends on malignancy or local aggressiveness: wide resection is indicated for malignant lesions, intralesional benign. Methods. We studied 82 patients with chordomas (55 cases) giant cell tumor (GCT) (27 treated between 1976 2005. All had IV antibiotic therapy amikacin teicoplanin. Surgery chordoma was resection; GCT excision. Infections were classified as immediate postoperative, early (within 6 months), late (more than months from surgery). Mean follow-up 9.5 years (range: 3–27 years). Some factors possibly influencing infection statistically analyzed by Kaplan Meier curves log-rank test. Results. No deep infections observed in Three died postoperative complications excluded this analysis. Of remaining 52 chordoma, 23/52 wound (44%) that required 1 more surgical debridements combined antibiotics, according to cultures. 16 (70%), occurred within 4 weeks postoperatively, 7 months. Most frequent bacteria Enterococcus (23%), Escherichia coli (20%), Pseudomonas aeruginosa (18%). 74% cases, multimicrobial. Level resection, previous treatment elsewhere, volume, age did not influence infection. Conclusion. Type prominent factor a major Operating procedure time correlated well. Resections imply high while excision does not. healed therapy. This focused review literature summarizes cervical spine anomalies found genetic syndromes. A comprehensive table syndromes their respective abnormalities included. Ten are summarized examples varied causes upper instability, kyphosis, global involvement.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (49)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....